Kenalog® is a well-established injectable therapy with a long-standing legacy in the treatment of inflammatory conditions, marketed across 15 countries under trusted brands including Kenalog®, Kenacort®, Trigon®, and Adcortyl®.
This acquisition further strengthens our Critical Care, Complex Generics portfolio and reinforces our commitment to delivering high-quality, hospital- focused medicines worldwide.
With a global distribution network reaching 6,000+ hospitals across more than 100 countries, the addition of Kenalog® represents a meaningful new growth opportunity particularly across the U.S., Europe, and Asia Pacific while maintaining the highest standards of quality and compliance.
